A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) for therapeutic radiopharmaceuticals
- 8 November 2025
- journal article
- Published by Elsevier in Applied Radiation and Isotopes
- Vol. 228, 112306
Abstract
No abstract availableKeywords
This publication has 68 references indexed in Scilit:
- Adverse reactions to therapeutic radiopharmaceuticalsApplied Radiation and Isotopes, 2024
- Real-world data from yttrium-90 ibritumomab tiuxetan treatment of relapsed or refractory indolent B-cell non-Hodgkin's lymphoma: J3Zi StudyAnnals of Hematology, 2023
- Lutetium Lu 177 Vipivotide Tetraxetan: First ApprovalMolecular Diagnosis & Therapy, 2022
- Strontium-89 chloride delivery for painful bone metastases in patients with a history of prior irradiationIrish Journal of Medical Science (1971 -), 2022
- Patient-Reported Adverse Events of Radiopharmaceuticals: A Prospective Study of 1002 PatientsDrug Safety, 2020
- Radium-223 dichloride in clinical practice: a reviewEuropean Journal of Nuclear Medicine and Molecular Imaging, 2016
- Strontium-89 (Sr-89) chloride in the treatment of various cancer patients with multiple bone metastasesInternational Journal of Clinical Oncology, 2013
- Safety and efficacy of repeat administration of samarium Sm‐153 lexidronam to patients with metastatic bone painCancer, 2006
- The reporting odds ratio and its advantages over the proportional reporting ratioPharmacoepidemiology and Drug Safety, 2004
- General aspects of the cellular response to low- and high-LET radiationEuropean Journal of Nuclear Medicine and Molecular Imaging, 2001